Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Pipeline
  • AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist
  • Pipeline

AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist

BioSpace

The lineup at the Alzheimer's Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurode

Neuroscience

Read full story

pharminent July 10, 2026 (Last updated: July 10, 2026)

BioSpace

The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurode

Neuroscience

Read full story

Post navigation

Previous: GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
Next: Hengrui-Kailera Oral GLP-1 Phase 3 Data Lands From China

Related Stories

  • Pipeline

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

pharminent August 11, 2026
  • Pipeline

Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

pharminent August 11, 2026
  • Pipeline

BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication

pharminent August 10, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.